Cytocast

Website: www.cytocast.com

Cytocast, a TechBio startup based in Budapest, Hungary, accelerates drug discovery by combining bioinformatics, AI, and large‑scale digital‑twin simulations to predict side effects at the start of R&D. Pharma, biotech and CRO teams use the Cytocast technology to de‑risk portfolios earlier and focus resources on safer candidates.

The CYTOCAST DIGITAL TWIN Platform™ models cellular systems to deliver breadth‑first side‑effect profiling for early‑stage small‑molecule programs, including combinations. Proteome‑based simulations reveal how candidates perturb cellular processes and provide actionable evidence to refine chemistries and improve safety. The platform has been validated through pilots with small and mid‑size partners. Currently, the following products are available for the clients’ tailored needs:

• Cytocast Screener™: Rank thousands of compounds by likely side effects to guide early discovery.
• Cytocast Optimizer™: After in vitro/in vivo, refine leads with comparative safety insights for preclinical decisions.
• Cytocast Nominator™: In‑depth analyses to support final candidate selection for trials.

Cytocast has raised €2.5M pre‑seed to date. We are opening a new €5M seed to expand product capabilities and market reach  with the goal of adoption at least 10 top‑100 pharma companies by 2027. Cytocast is a proud member of the Alliance for Artificial Intelligence in Healthcare (AAIH) and NVIDIA Inception.

SPOC Proteomics

Website: spoc.bio

SPOC Biosciences’ sensor-integrated proteome on chip (SPOC) synthesizes 192-1152 proteins (full-length, peptides, miniproteins) or antibody (VHH, scFv, Fab) drugs directly on biosensor chips (SPR, MALDI) for library-scale kinetic affinity screening supporting AI-enabled and traditional antibody discovery pipelines. SPOC KinetiKx datasets include on-rate (ka), off-rate (kd), affinity (KD), and residence time (t1/2). SPOC’s proprietary Protein NanoFactory production system utilizes cell-free expression with simultaneous capture-purification directly onto SPR chips, reducing time and cost for library-scale dataset generation compared to traditional recombinant protein workflows. SPOC HyperKinetiKx SPR Product Suite supports antibody drug discovery efforts for affinity ranking (AffiRank), affinity maturation (AffiBoost), epitope binning (EpiScope), epitope mapping (AminoMap) and polyreactivity screening (ReactiScan). SPOC HyperSynaptiKx SPR Product Suite is specifically designed to produce on-demand, large-scale, high-resolution datasets for validation and training in AI-driven drug discovery and development. HyperSynaptiKx SPR assays include lab-in-the-loop services for wet lab testing in DBTL cycles (BuildLoopIQ) and customer-defined antibody vs target library-on-library screening (ContactIQ). 

Helical

Website: www.helical-ai.com

Helical is the in-silico AI lab for pharma, powered by Bio Foundation Models. We enable pharma R&D teams to uncover novel targets and biomarkers, stratify patients, and accelerate RNA therapeutic design through virtual experiments that run in hours, not months. 

Already used by leading pharma companies, Helical turns Bio Foundation Models into a true experimentation system, enabling teams to personalize models, and run virtual hypotheses at scale before committing to the wet lab.